BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 23726266)

  • 1. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer.
    Ren S; Wang F; Shen J; Sun Y; Xu W; Lu J; Wei M; Xu C; Wu C; Zhang Z; Gao X; Liu Z; Hou J; Huang J; Sun Y
    Eur J Cancer; 2013 Sep; 49(13):2949-59. PubMed ID: 23726266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
    Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
    Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer.
    Rigau M; Ortega I; Mir MC; Ballesteros C; Garcia M; Llauradó M; Colás E; Pedrola N; Montes M; Sequeiros T; Ertekin T; Majem B; Planas J; Ruiz A; Abal M; Sánchez A; Morote J; Reventós J; Doll A
    Prostate; 2011 Dec; 71(16):1736-45. PubMed ID: 21520154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel urinary long non-coding RNA transcript improves diagnostic accuracy in patients undergoing prostate biopsy.
    Zhang W; Ren SC; Shi XL; Liu YW; Zhu YS; Jing TL; Wang FB; Chen R; Xu CL; Wang HQ; Wang HF; Wang Y; Liu B; Li YM; Fang ZY; Guo F; Lu X; Shen D; Gao X; Hou JG; Sun YH
    Prostate; 2015 May; 75(6):653-61. PubMed ID: 25597901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MD-miniRNA could be a more accurate biomarker for prostate cancer screening compared with serum prostate-specific antigen level.
    Xue D; Zhou CX; Shi YB; Lu H; He XZ
    Tumour Biol; 2015 May; 36(5):3541-7. PubMed ID: 25557788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.
    Ferro M; Bruzzese D; Perdonà S; Mazzarella C; Marino A; Sorrentino A; Di Carlo A; Autorino R; Di Lorenzo G; Buonerba C; Altieri V; Mariano A; Macchia V; Terracciano D
    Clin Chim Acta; 2012 Aug; 413(15-16):1274-8. PubMed ID: 22542564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
    Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
    Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
    Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml.
    Lucarelli G; Fanelli M; Larocca AM; Germinario CA; Rutigliano M; Vavallo A; Selvaggi FP; Bettocchi C; Battaglia M; Ditonno P
    Prostate; 2012 Nov; 72(15):1611-21. PubMed ID: 22430630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma.
    Zhang J; Zhao CY; Zhang SH; Yu DH; Chen Y; Liu QH; Shi M; Ni CR; Zhu MH
    Oncol Rep; 2014 Mar; 31(3):1157-64. PubMed ID: 24398877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.
    Chun FK; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Stillebroer AB; van Gils MP; Schalken JA; Fradet Y; Marks LS; Ellis W; Partin AW; Haese A
    Eur Urol; 2009 Oct; 56(4):659-67. PubMed ID: 19304372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood gene signature for early hepatocellular carcinoma detection in patients with chronic hepatitis B.
    Omar H; Lim CR; Chao S; Lee MM; Bong CW; Ooi EJ; Yu CG; Tan SS; Abu Hassan MR; Menon J; Muthukaruppan R; Singh M; Nik Abdullah NA; Ooi BP; Ding RP; Low EJ; Tan F; Novak D; Harris DF; Yang H; Merican I; Liew CC
    J Clin Gastroenterol; 2015 Feb; 49(2):150-7. PubMed ID: 25569223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?
    Tombal B; Andriole GL; de la Taille A; Gontero P; Haese A; Remzi M; Speakman M; Smets L; Stoevelaar H
    Urology; 2013 May; 81(5):998-1004. PubMed ID: 23523291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEACAM1, a novel serum biomarker for pancreatic cancer.
    Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
    Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating long non-coding RNAs in plasma of patients with gastric cancer.
    Arita T; Ichikawa D; Konishi H; Komatsu S; Shiozaki A; Shoda K; Kawaguchi T; Hirajima S; Nagata H; Kubota T; Fujiwara H; Okamoto K; Otsuji E
    Anticancer Res; 2013 Aug; 33(8):3185-93. PubMed ID: 23898077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer.
    Ren S; Liu Y; Xu W; Sun Y; Lu J; Wang F; Wei M; Shen J; Hou J; Gao X; Xu C; Huang J; Zhao Y; Sun Y
    J Urol; 2013 Dec; 190(6):2278-87. PubMed ID: 23845456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma.
    Baraniskin A; Nöpel-Dünnebacke S; Ahrens M; Jensen SG; Zöllner H; Maghnouj A; Wos A; Mayerle J; Munding J; Kost D; Reinacher-Schick A; Liffers S; Schroers R; Chromik AM; Meyer HE; Uhl W; Klein-Scory S; Weiss FU; Stephan C; Schwarte-Waldhoff I; Lerch MM; Tannapfel A; Schmiegel W; Andersen CL; Hahn SA
    Int J Cancer; 2013 Jan; 132(2):E48-57. PubMed ID: 22907602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miRNA-199a-3p in plasma as a potential diagnostic biomarker for gastric cancer.
    Li C; Li JF; Cai Q; Qiu QQ; Yan M; Liu BY; Zhu ZG
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S397-405. PubMed ID: 22956063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.